Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 08, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
A material change occurred in the notional allocation of Ordinary share ADRs held within the US Retirement Savings Plan ("The Plan"). Following a re-valuation of the cash element of the notional investment, the Administrators notified the registrant of a decrease in the notional allocation on April 04, 2008.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of general business risks. The transaction was executed at a price of $45.33 per ADR share and relates to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 04, 2008 (Notification date: April 08, 2008).
- Individual Involved: Dr R G Greig.
- Transaction Type: Decrease in notional allocation of Ordinary share ADRs.
- Price: $45.33 per ADR share.
- Context: Result of a re-valuation of the cash element within the US Retirement Savings Plan.